Cargando…

Adverse drug reactions and off-label and unlicensed medicines in children: a nested case?control study of inpatients in a pediatric hospital

BACKGROUND: Off-label and unlicensed (OLUL) prescribing has been prevalent in pediatric practice. Using data from a prospective cohort study of adverse drug reactions (ADRs) among pediatric inpatients, we aimed to test the hypothesis that OLUL status is a risk factor for ADRs. METHODS: A nested case...

Descripción completa

Detalles Bibliográficos
Autores principales: Bellis, Jennifer R, Kirkham, Jamie J, Thiesen, Signe, Conroy, Elizabeth J, Bracken, Louise E, Mannix, Helena L, Bird, Kim A, Duncan, Jennifer C, Peak, Matthew, Turner, Mark A, Smyth, Rosalind L, Nunn, Anthony J, Pirmohamed, Munir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231613/
https://www.ncbi.nlm.nih.gov/pubmed/24229060
http://dx.doi.org/10.1186/1741-7015-11-238
_version_ 1782344464871718912
author Bellis, Jennifer R
Kirkham, Jamie J
Thiesen, Signe
Conroy, Elizabeth J
Bracken, Louise E
Mannix, Helena L
Bird, Kim A
Duncan, Jennifer C
Peak, Matthew
Turner, Mark A
Smyth, Rosalind L
Nunn, Anthony J
Pirmohamed, Munir
author_facet Bellis, Jennifer R
Kirkham, Jamie J
Thiesen, Signe
Conroy, Elizabeth J
Bracken, Louise E
Mannix, Helena L
Bird, Kim A
Duncan, Jennifer C
Peak, Matthew
Turner, Mark A
Smyth, Rosalind L
Nunn, Anthony J
Pirmohamed, Munir
author_sort Bellis, Jennifer R
collection PubMed
description BACKGROUND: Off-label and unlicensed (OLUL) prescribing has been prevalent in pediatric practice. Using data from a prospective cohort study of adverse drug reactions (ADRs) among pediatric inpatients, we aimed to test the hypothesis that OLUL status is a risk factor for ADRs. METHODS: A nested case?control study was conducted within a prospective cohort study. Details of all medicines administered were recorded, including information about OLUL status. The odds ratio for OLUL medicines being implicated in a probable or definite ADR was calculated. A multivariate Cox proportional hazards regression model was fitted to the data to assess the influence that OLUL medicine use had on the hazard of an ADR occurring. RESULTS: A total of 10,699 medicine courses were administered to 1,388 patients. The odds ratio (OR) of an OLUL medicine being implicated in an ADR compared with an authorized medicine was 2.25 (95% confidence interval (CI) 1.95 to 2.59). Medicines licensed in children but given to a child below the minimum age or weight had the greatest odds of being implicated in an ADR (19% of courses in this category were implicated, OR 3.54 (95% CI 2.82 to 4.44). Each additional OLUL medicine given significantly increased the hazard of an ADR (hazard ratio (HR) 1.3 95% CI 1.2 to 1.3, P <0.001). Each additional authorized medicine given also significantly increased the hazard (HR 1.2 95% CI 1.2 to 1.3, P <0.001). CONCLUSIONS: OLUL medicines are more likely to be implicated in an ADR than authorized medicines. The number of medicines administered is a risk factor for ADRs highlighting the need to use the lowest number of medicines, at the lowest dose for the shortest period, with continual vigilance by prescribers, in order to reduce the risk of ADRs.
format Online
Article
Text
id pubmed-4231613
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42316132014-11-15 Adverse drug reactions and off-label and unlicensed medicines in children: a nested case?control study of inpatients in a pediatric hospital Bellis, Jennifer R Kirkham, Jamie J Thiesen, Signe Conroy, Elizabeth J Bracken, Louise E Mannix, Helena L Bird, Kim A Duncan, Jennifer C Peak, Matthew Turner, Mark A Smyth, Rosalind L Nunn, Anthony J Pirmohamed, Munir BMC Med Research Article BACKGROUND: Off-label and unlicensed (OLUL) prescribing has been prevalent in pediatric practice. Using data from a prospective cohort study of adverse drug reactions (ADRs) among pediatric inpatients, we aimed to test the hypothesis that OLUL status is a risk factor for ADRs. METHODS: A nested case?control study was conducted within a prospective cohort study. Details of all medicines administered were recorded, including information about OLUL status. The odds ratio for OLUL medicines being implicated in a probable or definite ADR was calculated. A multivariate Cox proportional hazards regression model was fitted to the data to assess the influence that OLUL medicine use had on the hazard of an ADR occurring. RESULTS: A total of 10,699 medicine courses were administered to 1,388 patients. The odds ratio (OR) of an OLUL medicine being implicated in an ADR compared with an authorized medicine was 2.25 (95% confidence interval (CI) 1.95 to 2.59). Medicines licensed in children but given to a child below the minimum age or weight had the greatest odds of being implicated in an ADR (19% of courses in this category were implicated, OR 3.54 (95% CI 2.82 to 4.44). Each additional OLUL medicine given significantly increased the hazard of an ADR (hazard ratio (HR) 1.3 95% CI 1.2 to 1.3, P <0.001). Each additional authorized medicine given also significantly increased the hazard (HR 1.2 95% CI 1.2 to 1.3, P <0.001). CONCLUSIONS: OLUL medicines are more likely to be implicated in an ADR than authorized medicines. The number of medicines administered is a risk factor for ADRs highlighting the need to use the lowest number of medicines, at the lowest dose for the shortest period, with continual vigilance by prescribers, in order to reduce the risk of ADRs. BioMed Central 2013-11-07 /pmc/articles/PMC4231613/ /pubmed/24229060 http://dx.doi.org/10.1186/1741-7015-11-238 Text en Copyright © 2013 Bellis et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Bellis, Jennifer R
Kirkham, Jamie J
Thiesen, Signe
Conroy, Elizabeth J
Bracken, Louise E
Mannix, Helena L
Bird, Kim A
Duncan, Jennifer C
Peak, Matthew
Turner, Mark A
Smyth, Rosalind L
Nunn, Anthony J
Pirmohamed, Munir
Adverse drug reactions and off-label and unlicensed medicines in children: a nested case?control study of inpatients in a pediatric hospital
title Adverse drug reactions and off-label and unlicensed medicines in children: a nested case?control study of inpatients in a pediatric hospital
title_full Adverse drug reactions and off-label and unlicensed medicines in children: a nested case?control study of inpatients in a pediatric hospital
title_fullStr Adverse drug reactions and off-label and unlicensed medicines in children: a nested case?control study of inpatients in a pediatric hospital
title_full_unstemmed Adverse drug reactions and off-label and unlicensed medicines in children: a nested case?control study of inpatients in a pediatric hospital
title_short Adverse drug reactions and off-label and unlicensed medicines in children: a nested case?control study of inpatients in a pediatric hospital
title_sort adverse drug reactions and off-label and unlicensed medicines in children: a nested case?control study of inpatients in a pediatric hospital
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231613/
https://www.ncbi.nlm.nih.gov/pubmed/24229060
http://dx.doi.org/10.1186/1741-7015-11-238
work_keys_str_mv AT bellisjenniferr adversedrugreactionsandofflabelandunlicensedmedicinesinchildrenanestedcasecontrolstudyofinpatientsinapediatrichospital
AT kirkhamjamiej adversedrugreactionsandofflabelandunlicensedmedicinesinchildrenanestedcasecontrolstudyofinpatientsinapediatrichospital
AT thiesensigne adversedrugreactionsandofflabelandunlicensedmedicinesinchildrenanestedcasecontrolstudyofinpatientsinapediatrichospital
AT conroyelizabethj adversedrugreactionsandofflabelandunlicensedmedicinesinchildrenanestedcasecontrolstudyofinpatientsinapediatrichospital
AT brackenlouisee adversedrugreactionsandofflabelandunlicensedmedicinesinchildrenanestedcasecontrolstudyofinpatientsinapediatrichospital
AT mannixhelenal adversedrugreactionsandofflabelandunlicensedmedicinesinchildrenanestedcasecontrolstudyofinpatientsinapediatrichospital
AT birdkima adversedrugreactionsandofflabelandunlicensedmedicinesinchildrenanestedcasecontrolstudyofinpatientsinapediatrichospital
AT duncanjenniferc adversedrugreactionsandofflabelandunlicensedmedicinesinchildrenanestedcasecontrolstudyofinpatientsinapediatrichospital
AT peakmatthew adversedrugreactionsandofflabelandunlicensedmedicinesinchildrenanestedcasecontrolstudyofinpatientsinapediatrichospital
AT turnermarka adversedrugreactionsandofflabelandunlicensedmedicinesinchildrenanestedcasecontrolstudyofinpatientsinapediatrichospital
AT smythrosalindl adversedrugreactionsandofflabelandunlicensedmedicinesinchildrenanestedcasecontrolstudyofinpatientsinapediatrichospital
AT nunnanthonyj adversedrugreactionsandofflabelandunlicensedmedicinesinchildrenanestedcasecontrolstudyofinpatientsinapediatrichospital
AT pirmohamedmunir adversedrugreactionsandofflabelandunlicensedmedicinesinchildrenanestedcasecontrolstudyofinpatientsinapediatrichospital